Emicizumab

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hemophilia A

Conditions

Hemophilia A

Trial Timeline

Apr 26, 2018 → Aug 29, 2025

NCT ID

NCT03315455

About Emicizumab

Emicizumab is a phase 3 stage product being developed by Roche for Hemophilia A. The current trial status is completed. This product is registered under clinical trial identifier NCT03315455. Target conditions include Hemophilia A.

What happened to similar drugs?

20 of 20 similar drugs in Hemophilia A were approved

Approved (20) Terminated (3) Active (0)

✅EmicizumabRocheApproved

✅BenefixPfizerApproved

✅Nonacog alfaPfizerApproved

✅moroctocog alfa (AF-CC) (ReFacto AF)PfizerApproved

✅Recombinant Factor IX CoagulationPfizerApproved

✅Moroctocog alfa(AF-CC)PfizerApproved

✅Factor IX recoveryPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05181618	Approved	Active	Jun 20, 2022	May 21, 2027	Severe Hemophilia A
NCT04431726	Phase 3	Active	Feb 4, 2021	May 18, 2030	Severe Hemophilia A
NCT04158648	Phase 3	Completed	Feb 10, 2020	Dec 19, 2025	Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor
NCT03315455	Phase 3	Completed	Apr 26, 2018	Aug 29, 2025	Hemophilia A
NCT03380780	Phase 1	Completed	Mar 12, 2018	Sep 18, 2018	Healthy Volunteers
NCT03191799	Phase 3	Completed	Sep 5, 2017	Nov 19, 2020	Hemophilia A

Competing Products

20 competing products in Hemophilia A

See all competitors

Product	Company	Stage	Hype Score
Emicizumab	Chugai Pharmaceutical	Phase 3	40
Emicizumab	Chugai Pharmaceutical	Phase 3	40
Emicizumab + rFVIIa + aPCC	Chugai Pharmaceutical	Phase 3	40
Human Coagulation Factor VIII	Chugai Pharmaceutical	Phase 3	47
Emicizumab	Chugai Pharmaceutical	Phase 3	47
Emicizumab + Factor VIII (FVIII)	Chugai Pharmaceutical	Phase 3	40
HEMLIBRA	Johnson & Johnson	Pre-clinical	26
Emicizumab	Roche	Phase 3	40
Emicizumab	Roche	Approved	47
Emicizumab	Roche	Phase 3	44
SPK-8011QQ	Roche	Phase 1/2	39
NXT007	Roche	Phase 1/2	39
Emicizumab Injection	Roche	Phase 2	35
Bypassing Agents + FVIII Replacement	Roche	Pre-clinical	26
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086	Pfizer	Phase 2	35
Nonacog Alfa (Genetical Recombination)	Pfizer	Pre-clinical	26
Refacto AF	Pfizer	Pre-clinical	18
PF-06838435/ fidanacogene elaparvovec	Pfizer	Phase 3	44
ReFacto AF	Pfizer	Phase 3	40
Nonacog alfa + Nonacog alfa	Pfizer	Phase 3	40